Many investors follow the popular "Sell in May" seasonal strategy, selling stocks at the end of April with the expectation of buying them back at the beginning of November. But after May's strong performance, investors who followed that strategy are feeling they missed out and that the strategy is therefore worthless.
In the following video, Fool contributor Dan Caplinger notes that the "Sell in May" strategy isn't just about a single month but rather covering a six-month span in which the worst losses historically haven't usually occurred during May. If you're going to follow the strategy, as Dan sees it, you have to give it a fair chance to working. Dan notes, though, that a better approach is to look closely at the fundamental reasons why stocks might do badly this summer and choose sectors that are most likely to drop as targets for trimming your holdings.
The best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of.�Click here now�to keep reading.
Top 10 Consumer Stocks To Watch For 2015: Bovis Homes Group PLC (BVS)
Bovis Homes Group PLC is a builder of traditional homes in England and Wales. The Company�� business involves the designing, building and selling of new homes for both private and public sector customers. The Company delivers projects such as Land acquisition, Planning, Legal, Design, Surveying, Engineering, Purchasing, Construction, Sales and marketing, Public relations and Customer service. Advisors' Opinion:- [By Inyoung Hwang]
Bovis Homes Group Plc (BVS) climbed 4 percent to 790 pence. Liberum Capital Ltd. raised its rating on the housebuilder to buy from hold. Persimmon Plc (PSN), the U.K.�� largest residential property developer, gained 2.5 percent to 1,255 pence.
Hot Long Term Companies To Own For 2014: Chelsea Therapeutics International Ltd.(CHTP)
Chelsea Therapeutics International, Ltd., a development-stage pharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutic products for the treatment of various human diseases. It is involved in developing Droxidopa, a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with primary autonomic failure and falls related to NOH in Parkinson?s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, adult attention deficit hyperactivity disorder, chronic fatigue syndrome, and freezing of gait in PD and down syndrome. The company intends to market its Droxidopa drug under the Northera brand name. It also engages in developing a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn?s disease, ankylosing spondylitis, uveitis, psoriatic arthritis, inflammatory bowel disease, cancer, and other immunological disorders. The company?s molecule products include a portfolio of metabolically inert antifolate molecules consisting of CH-1504 and CH-4051, which are orally available molecules with anti-inflammatory, autoimmune, and anti-tumor properties that inhibit various key enzymes required for cell proliferation; and a portfolio of dihydroorotate dehydrogenase, known as the I-3D portfolio, for applications in autoimmune diseases and transplantation. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina.
Advisors' Opinion:- [By Roberto Pedone]
Chelsea Therapeutics (CHTP)
is a specialty pharmaceutical company focused on acquisition, development and commercialization of pharmaceutical products for the treatment of a variety of human diseases. This stock closed up 9% to $2.89 in Thursday's trading session.Thursday's Range: $2.55-$2.98
52-Week Range: $0.73-$3.25
Thursday's Volume: 1.74 million
Three-Month Average Volume: 1.14 millionFrom a technical perspective, CHTP ripped sharply higher here right off its 50-day moving average of $2.55 with above-average volume. This stock has been uptrending strong for the last two months, with shares moving higher from its low of $1.78 t its recent high of $3.25. During that move, shares of CHTP have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CHTP within range of triggering a major breakout trade. That trade will hit if CHTP manages to take out some near-term overhead resistance levels at $3 to its 52-week high at $3.25 with high volume.
Traders should now look for long-biased trades in CHTP as long as it's trending above its 50-day at $2.55 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.14 million shares. If that breakout triggers soon, then CHTP will set up to enter new 52-week-high territory above $3.25, which is bullish technical price action. Some possible upside targets off that breakout are its next major overhead resistance levels at $4.21 to $4.40.
- [By Lauren Pollock]
Chelsea Therapeutics International Ltd.(CHTP) said an offering of 6.67 million shares priced at $3 each, a 9.9% discount to Tuesday’s close. The development-stage pharmaceutical company said it intends to use the proceeds to fund its droxidopa program, including regulatory and possible initial commercialization activity for its lead investigational drug candidate Northera, and for general corporate purposes. Shares dropped.
Hot Long Term Companies To Own For 2014: Cantel Medical Corp. (CMN)
Cantel Medical Corp. provides infection prevention and control products and services in the healthcare market. Its Endoscopy segment offers medical device reprocessing systems, disinfectants, detergents, and other supplies that are used to disinfect flexible endoscopes; and disposable infection control products for cleaning and disinfecting reusable components used in gastrointestinal endoscopy procedures. Its Water Purification and Filtration segment offers water purification equipment and services, filtration and separation products, and disinfectants for medical, pharmaceutical, biotech, beverage, and commercial industrial markets. This segment also offers hollow fiber membrane filtration and separation technologies for medical applications; and sterilants, disinfectants, and decontamination services used in various applications for infection prevention and control. The company�s Healthcare Disposables segment offers single-use infection prevention and control healthca re products, including face masks, sterilization pouches, towels and bibs, tray covers, saliva ejectors, germicidal wipes, plastic cups, and disinfectants used principally in the dental market; and biological and chemical indicators for sterility assurance monitoring services in the acute-care, alternate-care, and dental markets. Its Dialysis segment offers medical device reprocessing systems, sterilants/disinfectants, dialysate concentrates, and other supplies for renal dialysis. The company�s Specialty Packaging segment offers specialty packaging and thermal control products, as well as related compliance training for the transportation of infectious and biological specimens and thermally sensitive pharmaceutical, medical, and other products. Cantel Medical Corp. sells its products through its direct distribution network in the United States; and directly and through third-party distributors internationally. The company was founded in 1963 and is based in Little Falls, Ne w Jersey.
Advisors' Opinion:- [By Marc Bastow]
Infection protection and control company Cantel Medical (CMN) raised its semiannual dividend 21.6% to 4.5 cents per share, payable Jan. 31, 2014, to shareholders of record as of Jan. 17.
CMN Dividend Yield: 0.26%
Hot Long Term Companies To Own For 2014: Retractable Technologies Inc. (RVP)
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare industry in the United States and internationally. Its products include VanishPoint 0.5mL insulin syringes; 1mL tuberculin, insulin, and allergy antigen syringes; 0.5mL, 2mL, 3mL, 5mL, and 10mL syringes; small diameter tube adapters; blood collection tube holder; allergy trays; IV safety catheters; Patient Safe syringes; Patient Safe Luer Caps; and VanishPoint blood collection set, as well as autodisable syringes. The company sells its products to healthcare providers, such as acute care hospitals, alternate care facilities, doctors� offices, clinics, emergency centers, surgical centers, convalescent hospitals, veterans administration facilities, military organizations, public health facilities, and prisons. Retractable Technologies, Inc. distributes its products through a direct marketing network; and general line and specialty distributors, as well as through international distributors. The company was founded in 1994 and is headquartered in Little Elm, Texas.
Advisors' Opinion:- [By Holly LaFon]
Chip Skinner is a portfolio manager and principal of Royce & Associates, LLC, investment adviser to The Royce Funds. He is the portfolio manager of Royce Value Plus Fund (RVP) and an assistant portfolio manager of Royce Low-Priced Stock Fund (RLP). The thoughts and opinions expressed in the interview are solely his own and may differ from those of other Royce investment professionals, or the firm as a whole. There can be no assurance with regard to future market movements.
Hot Long Term Companies To Own For 2014: Cardiome Pharma Corporation(CRME)
Cardiome Pharma Corp., a life sciences company, engages in developing proprietary drugs to treat or prevent cardiovascular and other diseases. The company offers BRINAVESS, a product approved for marketing in the European Union, Iceland, and Norway for the conversion of recent onset atrial fibrillation to sinus rhythm in adults. It also has clinical programs, which focuses on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. The company has a phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C that completed phase I clinical trials for the treatment of infectious disease. In addition, Cardiome Pharma Corp. has pre-clinical projects that focus on cardiac diseases, ion channel conditions, and other indications. It also has a collaboration and license agreement with Merck & Co., Inc. (Merck), for the development and commercialization of vernakalant; and Astellas Pharma US, Inc. t o develop, make, and sell intravenous or injectable formulations of vernakalant in North America. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.
Advisors' Opinion:- [By John Udovich]
The biotech sector along with small cap biotech stocks Cardiome Pharma Corp (NASDAQ: CRME), Oncolytics Biotech, Inc (NASDAQ: ONCY), Vital Therapies Inc (NASDAQ: VTL) and TNI BioTech (OTCMKTS: TNIB) have all been producing their share of news this week for investors and traders alike to trade on. Moreover and while some 42 ��ife sciences��companies have gone public raising about $3 billion from investors so far this year, there are a growing number of biotechs pulling the plug on upcoming IPOs who are citing market conditions. With that in mind, here is a look at important news from the biotech sector and small cap biotech stocks this week:
- [By Bryan Murphy]
Back on March 13th I penned some less-than-well-received thoughts on Cardiome Pharma Corp. (NASDAQ:CRME). Basically, I was warning that CRME was just one stumble away from a fairly significant selloff. Given that so many traders were a fan of the biotech stock at the time, merely posing the possibility of a dip was something of a threat to my life and limb.
Hot Long Term Companies To Own For 2014: Kaman Corporation (KAMN)
Kaman Corporation operates in the aerospace and industrial distribution markets. The company?s Industrial Distribution segment distributes products, including bearings, mechanical and electrical power transmission, fluid power, motion control, and materials handling components. The segment offers its products through approximately 200 branches, distribution centers, and call centers in the United States, including Puerto Rico, as well as in Canada and Mexico. Its Aerospace segment produces and/or markets proprietary aircraft bearings and components; and complex metallic and composite aerostructures for commercial, military, and general aviation fixed and rotary wing aircraft. This segment also provides safing and arming solutions for missile and bomb systems for the U.S. and allied militaries; support for its maritime helicopters and medium-to-heavy lift helicopters; and offers engineering design, analysis, and certification services, as well as subcontracts helicopter wor k. Kaman Corporation also operates in the United Kingdom, Germany, Australia, and New Zealand. The company was founded in 1945 and is headquartered in Bloomfield, Connecticut.
Advisors' Opinion:- [By Rich Smith]
Bloomfield, Conn.-based Kaman Corporation (NYSE: KAMN ) looks likely to land a sizable contract with the New Zealand Ministry of Defense, the company announced late Thursday.
Hot Long Term Companies To Own For 2014: Furiex Pharmaceuticals Inc (FURX)
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company�� product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V.
Priligy (dapoxetine) is a drug developed for the on-demand treatment of premature ejaculation (PE). Dapoxetine is a short-acting, selective serotonin reuptake inhibitor (SSRI) designed to be taken only when needed one to three hours before sexual intercourse is anticipated rather than every day. Nesina (alogliptin) is a drug for the oral treatment of type 2 diabetes (T2D). Alogliptin is a DPP-4 inhibitor that slows the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
Fluoroquinolone drug candidate is a Phase II-ready novel fluoroquinolone antibiotic that is being developed by the Company for the treatment of complicated skin and skin structure infections, such as abscesses that occur deep in the skin layers and respiratory infections. This antibiotic has a spectrum of activity and is able to treat methicillin-resistant staphylococcus aureus (MRSA) infections. The Company is developing both oral and intravenous (IV) formulations. The Company is developing Mu Delta for treatment of diarrheal predominant irritable bowel syndrome (d-IBS). The Company is conducting a Phase II study on an oral formulation of Mu Delta.
The Company is developing PPD 10558 for the treatment of dyslipidemia. PPD 10558 has shown muscle safety in preclinical studies by minimizing the delivery of the drug to the muscle. The Company has filed an inve! stigational new drug (IND) application with the United States Food and Drug Association and completed five clinical studies.
Advisors' Opinion:- [By Lauren Pollock var popups = dojo.query(".socialByline .popC"); popups.forEach]
Forest Laboratories Inc.(FRX) agreed to acquire Furiex Pharmaceuticals(FURX) in a deal worth up to $1.33 billion that expands Forest Labs’ presence in gastroenterology. Furiex surged 28% to $102.21 premarket.
- [By CRWE]
Furiex Pharmaceuticals, Inc. (NASDAQ:FURX) reported dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).
No comments:
Post a Comment